A phase 2, open-label, randomized study of Pexa-Vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma - Breitbach, C J; Moon, A; Burke, J; Hwang, T H; Kirn, D H (Methods Mol Biol, 2015)